Pharmacogenomic approaches in the treatment of breast cancer by tamoxifen

Pakistan Journal of Pharmaceutical Sciences

Volumn 25, Issue 2, 2012, Pages 469-476

  Ameen, Sidra ^a   Qadir, Muhammad Imran ^a   Ahmad, Bashir ^b  

^a GC UNIVERSITY   (Pakistan)

^b BAHAUDDIN ZAKARIYA UNIVERSITY   (Pakistan)

Author keywords

Breast cancer; Pharmacogenomics; Tamoxifen

Indexed keywords

CYTOCHROME P450 2D6; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAS PROTEIN; TAMOXIFEN;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER PATIENT; CANCER RELAPSE; CANCER RESISTANCE; CANCER RISK; DEMETHYLATION; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG TRANSFORMATION; FEMALE; GENE MUTATION; GENETIC DIFFERENCE; GENOTYPE; HUMAN; HYDROXYLATION; PHARMACOGENOMICS; PREDICTION; PROGNOSIS; REVIEW;

BIOTRANSFORMATION; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; PHARMACOGENETICS; TAMOXIFEN;

EID: 84860614638     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Barrière J, Formento JL, Milano G and Ferrero JM (2010). CYP2D6 polymorphisms and tamoxifen: Therapeutic perspectives in the management of hormonodependent breast cancer patients. Bull. Cancer, 97: 311-320.
2. Beitelshees AL and McLeod HL (2006). Applying pharmacogenomics to enhance the use of biomarkers for drug effect and drug safety. Trends Pharmacol. Sci., 27: 498-502.
3. Beverage JN, Sissung TM, Sion AM, Danesi R and Figg WD (2007). CYP2D6 polymorphisms and the impact on tamoxifen therapy. J. Pharm. Sci., 96: 2224-2231.
4. Blackhall FH, Howell S and Newman B (2006). Pharmacogenetics in the management of breast cancer - prospects for individualised treatment. Fam. Cancer, 5: 151-157.
5. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L, Hillman G, Hayes DF, Stearns V and Flockhart DA (2006). Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. Clin. Pharmacol. Ther., 80: 61-74.
6. Brauch H (2007). Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol., 25: 5187-5193.
7. Brauch H, MÃ...rdter TE, Eichelbaum M and Schwab M (2009). Pharmacogenomics of tamoxifen therapy. Clin. Chem., 55: 1770-1782.
8. Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D and Boddy AV (2010). Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br. J. Cancer, 102: 1003-1009.
9. Briest S and Stearns V (2009). Tamoxifen metabolism and its effect on endocrine treatment of breast cancer. Clin. Adv. Hematol. Oncol., 7: 185-192.
10. Daly AK (2010). Genome-wide association studies in pharmacogenomics. Nat. Rev. Gene., 11: 241-246.
11. De Silva M, Senarath U, Gunatilake M and Lokuhetty D (2010). Prolonged breastfeeding reduces risk of breast cancer in Sri Lankan women: A case-control study. Cancer Epidemiol., 34: 267-73.
12. Dowsett M, Houghton J, Iden C, Salter J, Farndon J, A'Hern R, Sainsbury R and Baum M (2006). Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann. Oncol., 17: 818-826.
13. Eichelbaum M, Ingelman-Sundberg M and Evans WE (2006). Pharmacogenomics and individualized drug therapy. Annu. Rev. Med., 57: 119-137.
14. Gajalakshmi V, Mathew A, Brennan P, Rajan B, Kanimozhi VC, Mathews A, Mathew BS and Boffetta P (2009). Breastfeeding and breast cancer risk in India: A multicenter case-control study. Int. J. Canc., 125: 662-665.
15. Gaston C and Kolesar J (2008). Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer. Clin. Adv. Hematol. Oncol., 6: 825-833.
16. Goetz MP, Kamal A and Ames MM (2008). Tamoxifen pharmacogenomics: The role of CYP2D6 as a predictor of drug response. Clin. Pharmacol. Ther., 83: 160-166.
17. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EG, Nibbe AM, Desta Z, Nguyen A, Flockhart DA, Perez EA and Ingle JN (2007). The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat., 101: 113-121.
18. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA and Ingle JN (2005). Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol., 23: 9312-9318.
19. Hartman AR and Helft P (2007). The ethics of CYP2D6 testing for patients considering tamoxifen. Breast Cancer Res., 9: 103.
20. Hertz DL, McLeod HL and Hoskins JM (2009). Pharmacogenetics of breast cancer therapies. Breast, 18: 59-63.
21. Higgins MJ, Rae JM, Flockhart DA, Hayes DF and Stearns V (2009). Pharmacogenetics of tamoxifen: Who should undergo CYP2D6 genetic testing? J. Natl. Compr. Canc. Netw., 7: 203-213.
22. Hoskins JM, Carey LA and McLeod HL (2009). CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer, 9: 576-586.
23. Ingle JN (2008). Pharmacogenomics of tamoxifen and aromatase inhibitors. Cancer, 112: 695-699.
24. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF and Flockhart DA (2005). CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst. Monogr., 97: 30-39.
25. Kirchheiner J (2008). CYP2D6 phenotype prediction from genotype: Which system is the best? Clin. Pharmacol. Ther., 83: 225-227.
26. Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M, Tanigawara Y, Flockhart DA, Desta Z, Skaar TC, Aki F, Hirata K, Takatsuka Y, Okazaki M, Ohsumi S, Yamakawa T, Sasa M, Nakamura Y and Zembutsu H (2010). Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J. Clin. Oncol., 28: 1287-1293.
27. Kiyotani K, Mushiroda T, Sasa M, Bando Y, Sumitomo I, Hosono N, Kubo M, Nakamura Y and Zembutsu H (2008). Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci., 99: 995-999.
28. Lazarus P, Blevins-Primeau AS, Zheng Y and Sun D (2009). Potential role of UGT pharmacogenetics in cancer treatment and prevention: Focus on tamoxifen. Ann. NY Acad. Sci., 1155: 99-111.
29. Lo PK and Sukumar S (2008). Epigenomics and breast cancer. Pharmacogenomics, 9: 1879-1902.
30. Lukaszewicz K, Wtorek J, ABujnowski A and Skokowski J (2010). Monitoring of breast tissue thermo-ablation by means of impedance measurements. Iopscience. (Ahead of Print).
31. Lynn Henry N, Rae JM, Li L, Azzouz F, Skaar TC, Desta Z, Sikora MJ, Philips S, Nguyen AT, Storniolo AM, Hayes DF, Flockhart DA and Stearns V (2009). Consortium on Breast Cancer Pharmacogenomics Investigators Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Breast Cancer Res. Treat., 117: 571-575.
32. Mancinelli L, Cronin M and Sadée W (2000). Pharmacogenomics: The promise of personalized medicine. AAPS Pharm. Sci., 2: E4.
33. Marsh S and Liu G (2009). Pharmacokinetics and pharmacogenomics in breast cancer chemotherapy. Adv. Drug Deliv. Rev., 61: 381-387.
34. Mazzarino MC, Stivala F and Libra M (2006). Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv. Enzyme Regul., 46: 249-279.
35. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM and Franklin RA (2007). Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta., 1773: 1263-84.
36. Miller CR and McLeod HL (2007). Pharmacogenomics of cancer chemotherapy-induced toxicity. J. Support Oncol., 5: 9-14.
37. Nassiri I, Faghihi M and Tavassoli M (2009). Pharmacogenomic profiling of the PI3K/PTEN pathway in sporadic breast cancer. Iran. Biomed. J., 13: 79-86.
38. Nǎsui B, Popa M, Curşeu D, Sîrbu D and Ionut C (2009). Correlation of alcohol intake with breast cancer. Rev. Med. Chir. Soc. Med. Nat. Iasi., 113: 858-863.
39. Ntukidem NI, Nguyen AT, Stearns V, Rehman M, Schott A, Skaar T, Jin Y, Blanche P, Li L, Lemler S, Hayden J, Krauss RM, Desta Z, Flockhart DA and Hayes DF (2008). Consortium on Breast Cancer Pharmacogenomics. Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen. Clin. Pharmacol. Ther., 83: 702-710.
40. Panigrahi AR, Pinder SE, Chan SY, Paish EC, Robertson JF and Ellis IO (2004). The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J. Pathol., 204: 93-100.
41. Phillips KA, Veenstra DL, Oren E, Lee JK and Sadee W (2001). Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review. JAMA, 286: 2270-2279.
42. Polyak K (2007). Breast cancer: Origins and evolution. J. Clin. Invest., 117: 3155-3163.
43. Punglia RS, Burstein HJ, Winer EP and Weeks JC (2008). Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: A modeling analysis. J. Natl. Cancer Inst., 100: 642-648.
44. Qadir MI and Malik SA (2008). Plasma lipid profile in gynecologic cancers. Europ. J. Gyne. Oncol., 29: 158-161.
45. Ramón y Cajal T, Altés A, Paré L, del Rio E, Alonso C, Barnadas A and Baiget M (2010). Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res. Treat., 119: 33-38.
46. Rody A, Karn T, Gätje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhäberle E, Holtrich U, Kaufmann M and Ahr A (2006). Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures. Zentralbl Gynakol, 128: 76-81.
47. Rouzier R, Wagner P, Morandi P and Pusztai L (2005). Gene expression profiling of primary breast cancer. Curr. Oncol. Rep., 7: 38-44.
48. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Boländer J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M and Brauch H (2009). Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA, 302: 1429-1436.
49. Severino G and Del Zompo M (2004). Adverse drug reactions: Role of pharmacogenomics. Pharmacol. Res., 49: 363-373.
50. Shantakumar S, Terry MB, Teitelbaum SL, Britton JA, Millikan RC, Moorman PG, Neugut AI and Gammon MD (2007). Reproductive factors and breast cancer risk among older women. Breast Cancer Res. Treat., 102: 365-374.
51. Snedeker SM (2001). Pesticides and breast cancer risk: A review of DDT, DDE, and dieldrin. Environ. Health Perspect., 109: 35-47.
52. Snozek CL, O'Kane DJ and Algeciras-Schimnich A (2009). Pharmacogenetics of solid tumors: Directed therapy in breast, lung, and colorectal cancer: A paper from the 2008 William Beaumont Hospital symposium on molecular pathology. J. Mol. Diagn., 11: 381-390.
53. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z and Flockhart DA (2003). Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst., 95: 1758-1764.
54. Stearns V and Rae JM (2008). Pharmacogenetics and breast cancer endocrine therapy. CYP2D6 as a predictive factor for tamoxifen metabolism and drug response. Expert Rev. Mol. Med., 10: e34.
55. Tan SH, Lee SC, Goh BC and Wong J (2008). Pharmacogenetics in breast cancer therapy. Clin. Cancer Res., 14: 8027-8041.
56. Thomas FJ, McLeod HL and Watters JW (2004). Pharmacogenomics: The influence of genomic variation on drug response. Curr. Top. Med. Chem., 4: 1399-1409.
57. Tovey S, Dunne B, Witton CJ, Forsyth A, Cooke TG and Bartlett JM (2005). Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin. Cancer Res., 1: 4835-4842.
58. Ursin G, Ross RK, Sullivan-Halley J, Hanisch R, Henderson B and Bernstein L (1998). Use of oral contraceptives and risk of breast cancer in young women. Breast Cancer Res. Treat., 50: 175-84.
59. Vaclavikova R, Nordgard SH, Alnaes GI, Hubackova M, Kubala E, Kodet R, Mrhalova M, Novotny J, Gut I, Kristensen VN and Soucek P (2008). Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): Effects on its expression and clinic pathological characteristics in breast cancer patients. Pharmacogenet. Genomics, 18: 263-273.
60. Velentgas P and Daling JR (1994). Risk factors for breast cancer in younger women. J. Natl. Cancer Inst. Monogr., 16: 15-24.
61. Vesell ES (2000). Advances in pharmacogenetics and pharmacogenomics. J. Clin. Pharmacol., 40: 930-938.
62. Wang J, John EM, Horn-Ross PL and Ingles SA (2008). Dietary fat, cooking fat, and breast cancer risk in a multiethnic population. Nutr. Cancer, 60: 492-504.
63. Watters JW and McLeod HL (2003). Cancer pharmacogenomics: Current and future applications. Biochim. Biophys. Acta, 1603: 99-111.
64. Wegman P, Elingarami S, Carstensen J, Stål O, Nordenskjöld B and Wingren S (2007). Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res., 9: R7.
65. Weigelt B, Geyer FC and Reis-Filho JS (2010). Histological types of breast cancer: How special are they? Mol. Oncol. (Ahead of Print).
66. Weinshilboum R (2008). Pharmacogenomics of endocrine therapy in breast cancer. Adv. Exp. Med. Biol., 630: 220-231.
67. Welsh M, Mangravite L, Medina MW, Tantisira K, Zhang W, Huang RS, McLeod H and Dolan ME (2009). Pharmacogenomic discovery using cell-based models. Pharmacol. Rev., 61: 413-429.
68. Zhang W and Dolan ME (2010). Impact of the 1000 genomes project on the next wave of pharmacogenomic discovery. Pharmacogeno., 11: 249-256.